Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Career News – August 9, 2022 

View this email in your browser Career News – August 9, 2022  Alexion  Director, CMC Team Lead New Haven Associate Director, Biostatistics New Haven +72 more Arvinas ...

| By Kelley Gipson

EvolveImmune names president of R&D

EvolveImmune Therapeutics has appointed Jay S. Fine, Ph.D., as the company’s President of Research and Development. Dr. Fine is an accomplished biopharmaceutical executive with a successful...

| By Kelley Gipson

MediSynergics reports positive ongoing developments

MediSynergics reports positive ongoing preclinical development of “ketamine derivative” compounds MS-168 and MS-227 in pain, anxiety, behavior acute toxicity pharmacology, in vitro ADME, and structural elucidation...

| By Kelley Gipson

Alexion expansion will double lab floor space

Alexion, AstraZeneca’s Rare Disease group, has announced plans to expand in New Haven by leasing space at the new bioscience tower currently under construction at...

| By Kelley Gipson

Weekly Roundup – August 4, 2022 

View this email in your browser Weekly Roundup – August 4, 2022  Monday Arvinas announced John Northcott would join their team as the new Chief Commercial Officer. “I...

| By Kelley Gipson

Blavatnik Fellowship announces 2022/23 cohort

The Blavatnik Fellowship fifth cohort includes Emmanuel Aisabokhae, RPh, MBAv, Ashoka Madduri, PhD, MBA, and Yi Wang, PhD, MBA, who were selected from an extensive group of applicants...

| By Kelley Gipson

Pfizer testing next-generation COVID vaccines

Pfizer has raised the stakes of the COVID-19 vaccine business. The company has launched a midstage trial of the first in a planned series of next-generation,...

| By Kelley Gipson

Fast-track status for Qx lung transplantation drug

The development compound QXT-101 from Qx Therapeutics has been granted fast-track designation by the FDA for the treatment of Pulmonary Graft Dysfunction (PGD) following lung...

| By Kelley Gipson

Modifi Biosciences reports study validation

Modifi Biosciences reports that the journal Science has published a critical study validating the company’s novel oncology platform based on new classes of molecules that exploit tumor-associated DNA...

| By Kelley Gipson

Enko raises $70M for ‘safe crop protection’

Enko reports $70 million in Series C funding, bringing the company’s overall capital raised to date to $140 million. Mystic-based Enko will use the new funds...